Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 8/20 | 0.40 |
| ▸ | CDK1 | P06493 | 6/20 | 0.40 |
| ▸ | CDK9 | P50750 | 6/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | CDK4 | P11802 | 4/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 3/20 | 0.38 |
| ▸ | CDK7 | P50613 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764673 | 0.88 | JAK2 (0.37) | CDK2CDK1CDK4JAK2JAK1 | |
| SCHEMBL1633346 | 0.87 | CDK2 (0.43) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1631022 | 0.85 | JAK2 (0.54) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1633244 | 0.85 | PDE5A (0.43) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1633275 | 0.85 | CDK4 (0.50) | CDK2CDK1CCNA2CDK4JAK2 | |
| SCHEMBL13498359 | 0.82 | PDE5A (0.45) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1632485 | 0.82 | STK4 (0.43) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1571507 | 0.81 | CA2 (0.48) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1570742 | 0.80 | CA2 (0.50) | STK4CA2CDK2CDK1CDK9 | |
| SCHEMBL1633297 | 0.79 | TBK1 (0.47) | CDK2CDK1CDK9CCNA2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | STK4 66/4885CA2 3577/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.